Venous thromboembolism and atherosclerosis: Is there a link?

Journal of Thrombosis and Haemostasis

Volumn 5, Issue SUPPL. 1, 2007, Pages 270-275

  Prandoni, Paolo ^a  

^a UNIVERSITY OF PADUA MEDICAL SCHOOL   (Italy)

Author keywords

Atherosclerosis; Deep vein thrombosis; Pulmonary embolism; Risk factors; Venous thromboembolism

Indexed keywords

ACETYLSALICYLIC ACID; ANTINEOPLASTIC AGENT; ANTITHROMBOCYTIC AGENT; BLOOD CLOTTING FACTOR 7; D DIMER; FIBRINOGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; TAMOXIFEN; TISSUE PLASMINOGEN ACTIVATOR; VON WILLEBRAND FACTOR;

ACUTE HEART INFARCTION; AGE; ARTERY THROMBOSIS; ATHEROSCLEROSIS; BREAST CANCER; CANCER PREVENTION; CAROTID ARTERY DISEASE; CIGARETTE SMOKING; CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; DEEP VEIN THROMBOSIS; DIABETES MELLITUS; DISEASE ASSOCIATION; HEART FAILURE; HIGH RISK PATIENT; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPOTHESIS; INCIDENCE; ISCHEMIC HEART DISEASE; LUNG EMBOLISM; METABOLIC SYNDROME X; OBESITY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; STROKE; UNSPECIFIED SIDE EFFECT; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM;

EID: 34250758224     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2007.02467.x     Document Type: Review

References (60)

1. Singer DE, Albers GW, Dalen JE, Go AS, Halperin JL, Manning WJ. Antithrombotic therapy in atrial fibrillation: The seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004; 126: 429-56S.
2. Harrington RA, Becker RC, Ezekowitz M, Meade TW, O'Connor CM, Vorchheimer DA, Guyatt GH. Antithrombotic therapy for coronary artery disease: The seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004; 126: 513-48S.
3. Antithrombotic Trialist's Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high-risk patients. Br Med J 2002; 324: 71-86.
4. Hovens MM, Snoep JD, Tamsma JT, Huisman MV. Aspirin in the prevention and treatment of venous thromboembolism. J Thromb Haemost 2006; 4: 1470-5.
5. Janssen MC, den Heijer M, Cruysberg JR, Wollersheim H, Bredie SJ. Retinal vein occlusion: A form of venous thrombosis or a complication of atherosclerosis?. A meta-analysis of thrombophilic factors. Thromb Haemost 2005; 93: 1021-6.
6. Tsaloumas MD, Kirwan J, Vinall H, O'Leary MB, Prior P, Kritzinger EE, Dodson PM. Nine year follow-up study of morbidity and mortality in retinal vein occlusion. Eye 2000; 14: 821-7.
7. Prandoni P, Bilora F, Marchiori A, Bernardi E, Petrobelli F, Lensing AWA, Prins MH, Girolami A. An association between atherosclerosis and venous thrombosis. N Engl J Med 2003; 348: 1435-41.
8. Prandoni P, Lensing AWA, Cogo A, Cuppini S, Villalta S, Carta M, Cattelan AM, Polistena P, Bernardi E, Prins MH. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 1996; 125: 1-7.
9. Prandoni P, Villalta S, Bagatella P, Rossi L, Marchiori A, Piccioli A, Bernardi E, Girolami B, Simioni P, Girolami A. The clinical course of deep-vein thrombosis. Prospective long-term follow-up of 528 symptomatic patients. Haematologica 1997; 82: 423-8.
10. Schulman S, Rhedin AS, Lindmarker P, Carlsson A, Larfars G, Nicol P, Loogna E, Svensson E, Ljungberg B, Walter H. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. N Engl J Med 1995; 332: 1661-5.
11. Schulman S, Lindmarker P, Holmstrom M, Larfars G, Carlsson A, Nicol P, Svensson E, Ljungberg B, Viering S, Nordlander S, Leijd B, Jahed K, Hjorth M, Linder O, Beckman M. Post-thrombotic syndrome, recurrence, and death 10 years after the first episode of venous thromboembolism treated with warfarin for 6 weeks or 6 months. J Thromb Haemost 2006; 4: 734-42.
12. Prandoni P, Noventa F, Ghirarduzzi A, Pengo V, Bernardi E, Pesavento R, Iotti M, Tormene D, Simioni P, Pagnan A. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1626 patients. Haematologica 2007; 91: 199-205.
13. Heit J. Venous thromboembolism epidemiology: Implications for prevention and management. Semin Thromb Hemost 2002; 28 (Suppl. 2): 3-13.
14. Cogo A, Bernardi E, Prandoni P, Girolami B, Noventa F, Simioni P, Girolami A. Acquired risk factors for deep-vein thrombosis in symptomatic outpatients. Arch Intern Med 1994; 154: 164-8.
15. Libertiny G, Hands L. Deep venous thrombosis in peripheral vascular disease. Br J Surg 1999; 86: 907-10.
16. Goldhaber SZ, Grodstein F, Stampfer MJ, Manson JE, Colditz GA, Speizer FE, Willett WC, Hennekens CH. A prospective study of risk factors for pulmonary embolism in women. JAMA 1997; 277: 642-5.
17. Hansson PO, Eriksson H, Welin L, Svardsudd K, Wilhelmsen L. Smoking and abdominal obesity: Risk factors for venous thromboembolism among middle-aged men: "the study of men born in 1913". Arch Intern Med 1999; 159: 1886-90.
18. Stein PD, Beemath A, Olson RE. Obesity as a risk factor in venous thromboembolism. Am J Med 2005; 118: 978-80.
19. Petrauskiene V, Falk M, Waernbaum I, Norberg M, Eriksson JW. The risk of venous thromboembolism is markedly elevated in patients with diabetes. Diabetologia 2005; 48: 1017-21.
20. Hong C, Zhu F, Du D, Pilgram TK, Sicard GA, Bae KT. Coronary artery calcification and risk factors for atherosclerosis in patients with venous thromboembolism. Atherosclerosis 2005; 183: 169-74.
21. Vormittag R, Vukovich T, Stain M, Lehr S, Minar E, Pabinger I. Lipoprotein (a) in patients with spontaneous venous Thromboembolism. Thromb Res 2006; epub ahead of print.
22. Vaya A, Mira Y, Ferrando F, Contreras M, Estelles A, Espana F, Corella D, Aznar J. Hyperlipidaemia and venous thromboembolism in patients lacking thrombophilic risk factors. Br J Haematol 2002; 118: 255-9.
23. Marcucci R, Liotta AA, Cellai AP, Rogolino A, Gori AM, Giusti B, Poli D, Fedi S, Abbate R, Prisco D. Increased plasma levels of lipoprotein(a) and the risk of idiopathic and recurrent venous thromboembolism. Am J Med 2003; 115: 601-5.
24. Deguchi H, Pecheniuk NM, Elias DJ, Averell PM, Griffin JH. High-density lipoprotein deficiency and dyslipoproteinemia associated with venous thrombosis in men. Circulation 2005; 112: 893-9.
25. Tsai AW, Cushman M, Rosamond WD, Heckbert SR, Polak JF, Folsom AR. Cardiovascular risk factors and venous thromboembolism incidence. Arch Intern Med 2002; 162: 1182-9.
26. Glynn RJ, Rosner B. Comparison of risk factors for the competing risks of coronary heart disease, stroke, and venous thromboembolism. Am J Epidemiol 2005; 162: 975-82.
27. Decensi A, Maisonneuve P, Rotmensz N, Bettega D, Costa A, Sacchini V, Salvioni A, Travaglini R, Oliviero P, D'Aiuto G, Gulisano M, Gucciardo G, del Turco MR, Pizzichetta MA, Conforti S, Bonanni B, Boyle P, Veronesi U. Effect of tamoxifen on venous thromboembolic events in a breast cancer prevention trial. Circulation 2005; 111: 650-6.
28. Ageno W, Prandoni P, Romualdi E, Ghirarduzzi A, Dentali F, Pesavento R, Crowther M, Grandi AM, Venco A. The metabolic syndrome and the risk of venous thrombosis. A prospective, case control study. J Thromb Haemost 2006; 4: 1914-8.
29. Eliasson A, Bergqvist D, Bjorck M, Acosta S, Sternby NH, Ogren M. Prevalence and risk of venous thromboembolism in patients with verified arterial thrombosis: A population study based on 23 796 consecutive autopsies. J Thromb Haemost 2006; 4: 1897-902.
30. Wilhelmsen L, Svardsudd K, Korsan-Bengtsen K, Larsson B, Welin L, Tibblin G. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 1984; 311: 501-5.
31. Meade TW, Mellows S, Brozovic M, Miller GJ, Chakrabarti RR, North WR, Haines AP, Stirling Y, Imeson JD, Thompson SG. Haemostatic function and ischemic heart disease: Principal results from the Northwick Park Heart Study. Lancet 1986; 2: 533-7.
32. Thompson SG, Kienast J, Pyke SD, Haverkate F, van de Loo JC. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med 1995; 332: 635-41.
33. Miller GJ, Bauer KA, Barzegar S, Cooper JA, Rosenberg RD. Increased activation of the haemostatic system in men at high risk of fatal coronary heart disease. Thromb Haemost 1996; 75: 767-71.
34. Folsom AR, Wu KK, Rosamond WR, Sharrett AR, Chambless LE. Prospective study of hemostatic factors and incidence of coronary heart disease: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation 1997; 96: 1102-8.
35. Folsom AR, Aleksic N, Park E, Salomaa V, Juneja H, Wu KK. Prospective study of fibrinolytic factors and incident coronary heart disease: The Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler Thromb Vasc Biol 2001; 21: 611-7.
36. Koenig W, Rothenbacher D, Hoffmeister A, Griesshammer M, Brenner H. Plasma fibrin D-dimer levels and risk of stable coronary artery disease: results of a large case-control study. Arterioscler Thromb Vasc Biol 2001; 21: 1701-5.
37. Strano A, Hoppensteadt D, Walenga JM, Fareed J, Sabba C, Berardi E, Allegra C, Carlizza A, Binaghi F, Fronteddu F, Del Guercio R, Del Guercio M, Pinto A, Alletto G, Nazzari M, Ferrari PA. Plasma levels of the molecular markers of coagulation and fibrinolysis in patients with peripheral arterial disease. Semin Thromb Hemost 1996; 22 (Suppl. 1): 35-40.
38. De Buyzere M, Philippe J, Duprez D, Baele G, Clement DL. Coagulation system activation and increased D-dimer levels in peripheral arterial occlusive disease. Am J Hematol 1993; 43: 91-4.
39. Lowe GD, Fowkes FG, Dawes J, Donnan PT, Lennie SE, Housley E. Blood viscosity, fibrinogen, and activation of coagulation and leukocytes in peripheral arterial disease and the normal population in the Edinburgh Artery Study. Circulation 1993; 87: 1915-20.
40. Guthikonda S, Haynes WG. Homocysteine: Role and implications in atherosclerosis. Curr Atheroscler Rep 2006; 8: 100-6.
41. Oger E, Lacut K, Le Gal G, Couturaud F, Guenet D, Abalain JH, Roguedas AM, Mottier D. Hyperhomocysteinemia and low B vitamin levels are independently associated with venous thromboembolism: Results from the EDITH study: A hospital-based case-control study. J Thromb Haemost 2006; 4: 793-9.
42. Gaudstadnes M, Rudiger N, Moller J, Rasmussen K, Bjerregaard Larsen T, Ingerslev J. Thrombophilic predisposition in stroke and venous thromboembolism in Danish patients. Blood Coagul Fibrinol 1999; 10: 251-9.
43. Ye Z, Liu EHC, Higgins JPT, Keavney BD, Lowe GDO, Collins R, Danesh J. Seven haemostatic gene polymorphisms in coronary disease: Meta-analysis of 66 155 cases and 91 307 controls. Lancet 2006; 367: 651-8.
44. Foley PW, Irvine CD, Standen GR, Morse C, Smith FT, McGrath C, Baird RN, Lamont PM. Activated protein C, factor V Leiden and peripheral vascular disease. Cardiovasc Surg 1997; 5: 157-60.
45. Erkan D, Lockshin MD. Antiphospholipid syndrome. Curr Opin Rheumatol 2006; 18: 242-8.
46. Bank I, Libourel EJ, Middeldorp S, Hamulyak K, Van Pampus ECM, Koopman MMW, Prins MH, Van Der Meer J, Buller HR. Elevated levels of FVIII:C within families are associated with an increased risk for venous and arterial thrombosis. J Thromb Haemost 2005; 3: 79-84.
47. Michiels JJ, Berneman Z, Van Bockstaele D, van der Planken M, De Raeve H, Schroyens W. Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications. Semin Thromb Hemost 2006; 32: 174-207.
48. Levine MN. Prevention of thrombotic disorders in cancer patients undergoing chemotherapy. Thromb Haemost 1997; 78: 133-6.
49. Omine M, Kinoshita T, Nakakuma H, Maciejewski JP, Parker CJ, Socie G. Paroxysmal nocturnal hemoglobinuria. Int J Hematol 2005; 82: 417-21.
50. Maraha B, Peeters MF, van Aken BE, den Heijer M. Chlamydia pneumoniae, systemic inflammation and the risk of venous thrombosis. Diagn Microbiol Infect Dis 2002; 42: 153-7.
51. Lijfering WM, ten Cate MK, Sprenger HG, van der Meer J. Absolute risk of venous and arterial thrombosis in HIV-infected patients and effects of combination antiretroviral therapy. J Thromb Haemost 2006; 4: 1928-30.
52. Reich LM, Folsom AR, Key NS, Boland LL, Heckbert SR, Rosamond WD, Cushman M. Prospective study of subclinical atherosclerosis as a risk factor for venous thromboembolism. J Thromb Haemost 2006; 4: 1909-13.
53. van der Hagen PB, Folsom AR, Jenny NS, Heckbert SR, O'Meara ES, Reich LM, Rosendaal FR, Cushman M. Subclinical atherosclerosis and the risk of future venous thrombosis in the Cardiovascular Health Study. J Thromb Haemost 2006; 4: 1903-8.
54. Becattini C, Agnelli G, Prandoni P, Silingardi M, Salvi R, Taliani MR, Poggio R, Imberti D, Ageno W, Pogliani E, Porro F, Casazza F. A prospective study on cardiovascular events after acute pulmonary embolism. Eur Heart J 2005; 26: 77-83.
55. Prandoni P, Ghirarduzzi A, Prins MH, Pengo V, Davidson BL, Sorensen H, Pesavento R, Iotti M, Caviglia E, Iliceto S, Pagnan A, Lensing AWA. Venous thromboembolism and the risk of subsequent symptomatic atherosclerosis. J Thromb Haemost 2006; 4: 1891-6.
56. Bova C, Marchiori A, Noto A, Rossi V, Daniele F, Santoro C, Ricchio R, De Lorenzo R, Umbaca R, Prandoni P. Incidence of arterial cardiovascular events in patients with idiopathic venous thromboembolism. A retrospective cohort study. Thromb Haemost 2006; 96: 132-6.
57. Young L, Ockelford P, Milne D, Rolfe-Vyson V, McKelvie S, Harper P. Post treatment residual thrombus increases the risk of recurrent deep vein thrombosis and mortality. J Thromb Haemost 2006; 4: 1919-24.
58. Prandoni P, Lensing AWA, Prins MH, Bernardi E, Marchiori A, Bagatella P, Frulla M, Mosena L, Tormene D, Piccioli A, Simioni P, Girolami A. Residual venous thrombosis as a predictive factor of recurrent venous thromboembolism. Ann Intern Med 2002; 137: 985-90.
59. Squizzato A, Romualdi E, Ageno W. Why should statins prevent venous thromboembolism? A systematic literature search and a call for action J Thromb Haemost 2006; 4: 1925-7.
60. Agnelli G, Becattini C. Venous thromboembolism and atherosclerosis: common denominators or different diseases? J Thromb Haemost 2006; 4: 1886-90.